期刊文献+

护理干预对糖尿病患者遵医行为的影响 被引量:4

原文传递
导出
摘要 糖尿病是以高血糖为特征的代谢性疾病,是由于胰岛素分泌缺陷或其生物作用受损引起。我科对部分糖尿病患者采用护理干预,取得满意效果,报告如下。1资料与方法1.1临床资料选择2015年5月~2016年5月我院内分泌科入院治疗的糖尿病患者248例为研究对象,均确诊为糖尿病。诊断标准:空腹血糖≥7.0 mmol/l(126 mg/dl)和/或餐后2 h血糖≥11.1 mmol/l(200 mg/dl)^([1])。
作者 许明霞
出处 《中国冶金工业医学杂志》 2018年第5期531-532,共2页 Chinese Medical Journal of Metallurgical industry
  • 相关文献

参考文献3

二级参考文献17

  • 1侯玉华.糖尿病患者的健康教育和社区护理干预探讨[J].国际护理学杂志,2006,25(3):183-185. 被引量:33
  • 2KDOKI.KDOQI Clinical Prac'tice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease[J].Am J Kidney Dis,2007,49 (Suppl 2):S12-154.
  • 3Rodbard HW,Blonde L,Braithwaite SS,et al.American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus[J].Endocr Pract,2007,13(Suppl 1):1 -68.
  • 4Mancia G,De Backer G,Dominiczak A,et al.2007 Guidelines for the management of arterial hypertension:The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)[J].Eur Heart J,2007,28 (12):1462-1536.
  • 5Rodby RA,Rohde RD,Clarke WR,et al.The Irbesartan type Ⅱ diabetic nephropathy trial:study design and baseline patient charactoristics.For the Collaborative Study Group[J].Nephrol Dial Transplant,2000,15:487-497.
  • 6Brenner BM,Cooper ME,de Zeenw D,et al.Effects of Inesrtan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy[J].N Engl J Med,20010345:861-869.
  • 7Viberti G,Whecldon NM.Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus:a blood pressure-independent effect[J].Circulation,2002,106:672-678.
  • 8Rossing K,Christensen PK,Andersen S,et al.Comparative effects of lrbosartan on ambulatory and office blood pressure:a substudy of ambulatory blood pressure from the lrbesartan in Patients with Type 2 Diabetes and Micreslbuminuria study[J].Diabetes Care,2003,26:569-574.
  • 9Diercks GF,Janssen WM,van Boven AJ,et al.Rationale,design,and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive,nonhypercholesterolemic subjects with microalbuminuria(the Prevention of REnal and Vascular ENdstage Disease Intervention Trial[PREVEND IT])[J].Am J Cardiol,2000,86:635-638.
  • 10Ansquer JC,Fouchor C,Rattier S,et al.Fenofibrate reduces progresaion to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes:results from the Diabetes Atherosclerosis Intervention Study (DAIS).[J] Am J Kidney Dis,2005,45:485-493.

共引文献117

同被引文献12

引证文献4

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部